Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Gap Down - Should You Sell?

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report)'s stock price gapped down before the market opened on Friday . The stock had previously closed at $60.00, but opened at $57.23. Zealand Pharma A/S shares last traded at $57.23, with a volume of 100 shares trading hands.

Analysts Set New Price Targets

Separately, William Blair raised Zealand Pharma A/S from a "hold" rating to a "strong-buy" rating in a research note on Friday, March 7th.

Zealand Pharma A/S Trading Down 1.4%

The business's 50-day simple moving average is $66.33 and its 200-day simple moving average is $84.06. The company has a market cap of $4.20 billion, a PE ratio of -23.75 and a beta of 0.74. The company has a current ratio of 25.10, a quick ratio of 25.07 and a debt-to-equity ratio of 0.03.

Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.67) earnings per share for the quarter, topping analysts' consensus estimates of ($0.77) by $0.10. Zealand Pharma A/S had a negative net margin of 2,127.09% and a negative return on equity of 13.40%. The business had revenue of $1.14 million for the quarter, compared to the consensus estimate of $248.61 million. As a group, analysts expect that Zealand Pharma A/S will post -2.19 EPS for the current fiscal year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.